CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Stroke and transient ischaemic attack - Management
What drug interactions should I be aware of with dipyridamole?
- Cholinesterase inhibitors:
- Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.
- Evidence is sparse. However, dipyridamole should be used with caution in people with myasthenia gravis, as there is a case report of dipyridamole increasing myasthenic symptoms [Baxter, 2008].
- Antihypertensive drugs:
- Because of its vasodilating activity, the manufacturer of dipyridamole (Persantin Retard®) warns that the drug may increase the hypotensive effect of antihypertensive drugs.
- Dipyridamole does not appear to interact with warfarin:
- The manufacturer of Persantin Retard® reported that bleeding was no greater in frequency or severity than that observed when warfarin was administered alone.
[ABPI Medicines Compendium, 2007b]
© NHS Institute for Innovation and Improvement